Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes.
Cristiane J Gomes-LimaDi WuSarika N RaoSree PunukolluRama HritaniAlexander ZeymoHala DeebMihriye MeteEdward F AulisiDouglas Van NostrandJacqueline JonklaasLeonard WartofskyKenneth D BurmanPublished in: Journal of the Endocrine Society (2018)
The prevalence of brain metastases of DTC in our institutions was 0.3% over 15 years. The median survival time after diagnosis of brain metastases was 19 months. In our study population, the use of TKI improved the survival rates.